

PRESS *Release*



FOR IMMEDIATE RELEASE

**PRESS RELEASE
VIA FILING SERVICES CANADA**

TSX VENTURE SYMBOL: DOC

October 9, 2009 15:30 ET

IHP Announces Proposed Transaction With Patient Home Monitoring (StanCap Holdings I Limited)

TORONTO, ONTARIO--(Marketwire – October 9, 2009) -

NOT FOR DISTRIBUTION IN THE UNITED STATES OR THROUGH UNITED STATES WIRE SERVICES.

International Health Partners Inc. ("IHP") (TSX-V:DOC) is pleased to announce that it has signed a letter of intent dated September 23, 2009 (the "LOI") to acquire Patient Home Monitoring, a British Columbia company incorporated on July 16, 2009 as Stancap Holdings I Limited ("PHM"). PHM is a healthcare services company focused exclusively on penetrating the emerging Medicare-reimbursed U.S. healthcare market for in-home-monitoring of patients on blood thinners. The transaction is a Reverse Takeover under the policies of the TSX Venture Exchange and is subject to regulatory and shareholder approval.

The PHM Target Market

According to the American Heart Association there are over 4 million patients in the United States being treated with oral anticoagulants, such as warfarin or Coumadin®. Many of these patients are on blood thinners for extended periods of time or for the rest of their lives. Physicians who prescribe blood thinners monitor patient blood coagulation levels frequently through a Prothrombin Time (PT) test and it's International Normalized Ratio (INR) to ensure effective treatment, and to avoid serious and often life threatening medical conditions associated with excessive or inadequate coagulation levels. Dangers associated with inadequate or excessive coagulation levels include clotting or internal bleeding that may lead to strokes, cardiac events and other conditions. Until recently, physicians were limited to PT/INR testing in a laboratory or medical centre, which inconvenienced patients and added time and administrative logistics to the treatment process.

Recently, the United States Department of Health and Human Services' Centres for Medicare & Medicaid Services ("Medicare") revised it's National Coverage Decision (NCD) for Home Anticoagulation Monitoring. Reimbursement now covers home PT/INR monitoring for chronic oral anticoagulation management for patients with mechanical heart valves, chronic atrial fibrillation, or thromboembolism (inclusive of deep vein thrombosis and pulmonary embolism).

Medicare concluded that more frequent and readily accessible self-administered in-home testing would lead to better medical outcomes and lower overall costs to treat these patients. Because of this recent expansion of coverage, cardiologists are seeking to partner with companies that can provide in-home monitoring services. Currently, only a small percentage of the patient population has been enrolled for in-home monitoring. While relatively small today, reimbursed in-home monitoring is an emerging market that is expected to represent revenue potential exceeding one billion dollars per year if one in five patients is monitored from the home.

The PHM Service Business

As a US-based operation, PHM will focus on servicing cardiologists in the US who treat patients with chronic conditions requiring blood thinners. PHM plans to supply patients with in-home diagnostic equipment and disposables supplied by a large and well known pharmaceutical and device company which is one of the three leading suppliers in the market. Ultimately, PHM will provide weekly data from the equipment to the cardiologist who is responsible for treating the patients. PHM anticipates that many patients will require in-home monitoring in the near future, given the advantages in frequency of testing and convenience as well as full coverage for the service by Medicare.

In exchange for these services, PHM will receive a monthly payment from Medicare or the patient's private health insurer for between \$125 and \$160 per patient depending on the location. Physicians also receive monthly payments for reviewing the data provided by PHM for patients that are monitored at home.

PHM Competitive Advantages

PHM has a business model designed to penetrate this new in-home market with significant barriers to entry and competitive advantages.

Demand-side Advantage: As a key competitive advantage, cardiologists who use PHM's services may qualify to participate in the PHM opportunity, in addition to the professional fees they would receive in treating their patients. PHM intends to be one of the first well-capitalized companies that will focus exclusively on in-home coagulation monitoring in partnering with cardiologists to supply meters and monitoring services to their patients.

Supply-side Advantage: PHM is finalizing a vendor distribution arrangement with a large and well known pharmaceutical and device company which is one of the three leading suppliers in the market. This company has a worldwide distribution right to provide coagulation diagnostic meters and strips manufactured by CoaguSense, Inc. ("CoaguSense") CoaguSense, also a shareholder in PHM, is a private company that has designed an intellectual property-protected meter.

Current PHM Ownership Structure

Stanmore Capital Holdings, LLC ("Stanmore"), a Washington incorporated US investment group, and CoaguSense, a California incorporated company, or Directors of CoaguSense, collectively own, directly or indirectly, more than fifty percent (50%) of PHM.

CoaguSense is a private company which manufactures and owns the intellectual property for the meter and strips for which a large and well known pharmaceutical and device company acts as exclusive worldwide distributor. This exclusive, global distributor is one of the three leading suppliers in the market.

A number of Canadian private investors are shareholders of PHM. None own, directly or indirectly, more than ten per cent of the issued and outstanding shares. No insiders of PHM hold a beneficial interest in any of these shareholders.

Stanmore is a US investment firm, and following completion of the transaction and financing, it is anticipated that Stanmore will be the only shareholder that will own, directly or indirectly, more than ten per cent of the outstanding shares. The Principals of Stanmore who are expected to become members of the Board of Directors of the Resulting Issuer are Roger Greene and Michael Dalsin.

Mr. Greene is a resident of Orange County, California. He has undergraduate and law degrees from Harvard. He has extensive experience in the international and US healthcare markets. Mr. Dalsin is also a resident of Orange County, California. He has an undergraduate degree from University of Wisconsin. He has extensive experience in both US and international healthcare investments.

Stanmore Capital Partners, Inc., a merchant banking group based in California specializing in US medical services companies, has been retained by PHM to serve as lead advisor.

The Transaction

The proposed Transaction between IHP and PHM would constitute a Reverse Takeover pursuant to Policy 5.2 of the TSX Venture Exchange (the "Exchange"). In addition and concurrent with the Transaction, IHP and PHM have agreed that IHP will have sold off or assigned all of its current operations including substantially all assets and liabilities in exchange for an assumption of all liabilities and certain other consideration, so that at the conclusion of the transaction, PHM will be IHP's sole business, and will have raised, on a best efforts brokered private placement basis, approximately \$5,000,000 in additional working capital (the "**Financing**"). The Transaction has been negotiated on an arm's length basis.

The Financing will be made to address the new and rapidly growing market, where first mover advantage is important. A substantial portion of the funds will be used to purchase the monitors and supplies which PHM must supply to patients conducting home testing. Proceeds will also be used to develop call centres to assist in monitoring and support, integrate information technology systems and software to permit efficient communication of information to cardiologists, retain key personnel, further secure the strategic partnership with the manufacturer, and provide working capital for marketing and general operations.

IHP is a medical "Practice Management Company" in the business of evaluating and consolidating medical facilities. The Company operates two medical clinics in the Province of Alberta that will be sold as a condition of completing the Transaction. Insiders of IHP own less than 10% of the outstanding equity of PHM. It is expected that, subject to the receipt of requisite shareholder, director and regulatory approvals IHP shall seek to change its name to "Patient Home Monitoring Corp." and will also seek to appoint a number of new directors to the Board.

The Transaction and Financing

PHM and IHP have proposed that IHP acquire all of the issued and outstanding shares of PHM to become a wholly-owned subsidiary of IHP ("Subco"). Based on the current capitalization of PHM and IHP, and the proposed issue of approximately 23.917 IHP common shares of IHP to former PHM shareholders for each IHP common share presently outstanding, IHP will have approximately 28,700,000 common shares outstanding, of which 27,500,000 common shares

will be held by former PHM shareholders and approximately 1,200,000 common shares will be held by existing IHP shareholders. The deemed value of shares to be issued to the former PHM shareholders is \$5,500,000 or \$0.20 per share.

IHP and PHM have agreed that the closing of the Transaction is also conditional upon IHP completing the Financing. Bloom Burton & Co. Inc. of Toronto, Canada ("BB") has presented an engagement letter dated September 23, 2009 to act as lead agent in the Financing that is to be completed as a condition of the Transaction. The offering is to be priced within the context of the market that is anticipated to be \$0.20 per common share, for an additional listing of 25,000,000 common shares. Up to 50% of the Financing may be subscribed for by former PHM shareholders and their associates. Other terms and conditions of the Financing have yet to be finalized.

As lead agent, BB will receive a commission equal to 8% of the gross proceeds received pursuant to the Financing, and compensation warrants to purchase a number of common shares of IHP equal to 8% of the common shares sold pursuant to the Financing, exercisable at \$0.20 for a period of sixty months from the closing of the Financing. IHP has also agreed to pay BB's legal fees for private placement due diligence as well as additional due diligence expenses, plus BB's reasonable, pre-approved travel and other expenses.

The IHP common shares to be issued to PHM pursuant to the Transaction was determined in arm's length negotiations between IHP and PHM based on certain factors such as (i) the current business condition of PHM, (ii) the investment made to date in developing PHM's business, (iii) the anticipated future profits of PHM, and (iv) the expertise of the management of PHM. The Transaction structure may be revised by mutual agreement of the parties to accommodate efficiencies for various legal structures, tax and accounting treatment and securities regulation. All details of the merger transaction, concurrent financing, new board composition, incentive-based stock options and other matters as required will be disclosed in a Management Information Circular that will be filed with the TSX Venture Exchange for review prior to mailing to shareholders.

Selected Financial Information

The financial statements of IHP may be viewed on SEDAR at www.sedar.com.

A comprehensive press release with additional details on the proposed board of directors and management, as well as financial information of PHM will be issued once such information becomes available.

Sponsorship

It is anticipated that sponsorship of the Transaction will be required by the TSX Venture Exchange. Once this is confirmed, IHP will issue a further News Release upon appointment of a Sponsor.

Trading Halt

IHP's common shares are currently halted and will remain so until the documentation required by the Exchange for the proposed Transaction is filed. Investors are cautioned that trading in the securities of IHP should be considered to be highly speculative. International Health Partners Inc. is governed by the policies of the Exchange.

This press release contains certain forward-looking statements that reflect the current views and/or expectations of International Health Partners Inc. with respect to performance, business

and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly from those disclosed herein. Investors are cautioned not to rely on these forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this new release, and IHP does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.

Completion of the Transaction is subject to a number of conditions, including but not limited to, Exchange acceptance and if applicable disinterested shareholder approval. If required, the Transaction cannot close until the prescribed shareholder approval is obtained. There can be no assurance that the transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the transaction, any information released or received with respect to the transaction may not be accurate or complete and should not be relied upon. Trading in the securities of IHP should be considered highly speculative. The TSX Venture Exchange has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.

For more information, please contact
International Health Partners Inc.
Mr. Brock Bundy, Director
Tel: (416) 581-8850 x 4105